Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France
Recruiting
- Conditions
- Tuberous Sclerosis Complex
- Registration Number
- NCT02887781
- Lead Sponsor
- University Hospital, Brest
- Brief Summary
This study aims to investigate the factors (clinical, care-related and genetic) affecting renal outcome in patients with TSC (Tuberous sclerosis complex)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evolution of the renal function estimated by the MDRD GFR 18 months after inclusion
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are involved in renal angiomyolipoma progression in TSC patients?
How do mTOR inhibitors compare to standard care in managing TSC-related renal complications?
Are there specific biomarkers for early detection of renal dysfunction in TSC patients?
What are the long-term adverse events associated with TSC treatment in observational studies?
What combination therapies show promise for TSC-related renal angiomyolipoma management?
Trial Locations
- Locations (2)
CHU Brest
🇫🇷Brest, France
CHU Rennes
🇫🇷Rennes, France
CHU Brest🇫🇷Brest, FranceYannick LE MEUR, MD PhDPrincipal Investigator